



# Transcranial magnetic stimulation treatment in Alzheimer's disease: a meta-analysis of its efficacy as a function of protocol characteristics and degree of personalization

Arianna Menardi<sup>1,2</sup> · Lisa Dotti<sup>3</sup> · Ettore Ambrosini<sup>1,2,3</sup> · Antonino Vallesi<sup>1,2</sup>

Received: 29 March 2022 / Revised: 14 June 2022 / Accepted: 14 June 2022 / Published online: 4 July 2022  
© The Author(s) 2022

## Abstract

Alzheimer's disease (AD) represents the most common type of neurodegenerative disorder. Although our knowledge on the causes of AD remains limited and no curative treatments are available, several interventions have been proposed in trying to improve patients' symptomatology. Among those, transcranial magnetic stimulation (TMS) has been shown a promising, safe and noninvasive intervention to improve global cognitive functioning. Nevertheless, we currently lack agreement between research studies on the optimal stimulation protocol yielding the highest efficacy in these patients. To answer this query, we conducted a systematic literature search in PubMed, PsycINFO and Scopus databases and meta-analysis of studies published in the last 10 years (2010–2021) according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Differently from prior published meta-analytic work, we investigated whether protocols that considered participants-specific neuroimaging scans for the selection of *individualized* stimulation targets held more successful outcomes compared to those relying on a *generalized* targeting selection criteria. We then compared the effect sizes of subsets of studies based on additional protocol characteristics (frequency, duration of intervention, number of stimulation sites, use of concomitant cognitive training and patients' educational level). Our results confirm TMS efficacy in improving global cognitive functioning in mild-to-moderate AD patients, but also highlight the flaws of current protocols characteristics, including a possible lack of sufficient personalization in stimulation protocols.

**Keywords** Alzheimer's disease · Transcranial magnetic stimulation · Personalized medicine · Intervention efficacy · Individualized stimulation

## Introduction

Alzheimer's disease (AD) represents the most common type of neurodegenerative disease [1]. Due to its multifactorial nature, the gradual cognitive decline is associated with the interaction of multiple pathological alterations, including brain atrophy, amyloid plaques deposition, and

neurofibrillary tangles formation, which ultimately lead to a clinical diagnosis of dementia [2–6]. Despite abnormal amyloid markers being recognized as an early indicator or risk factor of AD, it has been suggested to refrain from giving an AD diagnosis to patients with abnormal protein builds-up but normal cognitive functioning [7]. Indeed, the National Institute on Aging and Alzheimer's Association (NIA-AA) recognizes AD as a spectrum characterized by widespread cognitive deficits that extend beyond the well-known memory decline [8]. Yet, little is known about the causes of Alzheimer's disease and no curative treatments are available [9]. In this complex framework, some unmodifiable risk factors are acknowledged, such as age, family history, cardiovascular pathologies and genetic factors, such as the presence of the Apolipoprotein E4 (APOE4) allele [10–13]. On the other hand, modifiable risk factors are represented by poor diet choices [14, 15], lack of physical exercise [16, 17] and cognitive stimulation [18], as well as hearing loss

Arianna Menardi and Lisa Dotti contributed equally to this work.

✉ Arianna Menardi  
arianna.menardi@gmail.com

<sup>1</sup> Department of Neuroscience, University of Padova, 35121 Padua, Italy

<sup>2</sup> Padova Neuroscience Center, University of Padova, Padua, Italy

<sup>3</sup> Department of General Psychology, University of Padova, Padua, Italy

and the exposure to environmental stress [19], among others. From this perspective, nonpharmacological treatments may play an important role, especially in the form of preventive medicine via general lifestyle choices, as well as the effective management of overall health conditions and cognitive wellness [20].

As a form of nonpharmacological intervention, noninvasive brain stimulation techniques (NIBS) have gathered substantial interest. NIBS interventions rely on brain plasticity mechanisms, with which neural pathways and circuits can be modified as a function of both internal (bodily) and external inputs, such as in response to environmental or controlled experimental stimuli, as in the case of NIBS interventions [21]. This phenomenon is present throughout the life span [21, 22], and it mimics the mechanisms of long-term potentiation/depression in glutamatergic synapses, leading to the NIBS-induced changes to outlast the period of stimulation [23]. Since altered excitability and plasticity are a hallmark in many neurological pathologies in modulating the relationship between brain insults and clinical outcome [24–26], great interest has been directed toward the possibility of leveraging on brain plasticity mechanisms to generate enduring modulations of activity in anatomical systems impacted by the disease or in spared neural networks interconnected with the former [27].

The most common form of NIBS is transcranial magnetic stimulation (TMS), consisting of a brief discharge of an electric current through a coil, inducing a focal magnetic field, that penetrates the scalp and the skull and secondarily generates an electric current, in accordance with the Faraday's principle of electromagnetic induction [28]. Depending on the frequency of stimulation with repetitive TMS (rTMS), either excitation ( $\geq 5$  Hz: high-frequency rTMS) or inhibition ( $\leq 1$  Hz: low-frequency rTMS) of the underlying neuronal activity of the stimulated area can be induced [29, 30]. Although rTMS is widely used, current clinical guidelines state a level A evidence (definite efficacy) only for the management of few pathologies, such as neuropathic pain, depression and hand motor recovery in the post-acute stages of stroke [31]. Evidence is less strong, yet promising, for the use of TMS in other pathologies, such as obsessive compulsive disorder [32]. On the other hand, the use of rTMS in AD is still debated due to considerable heterogeneity across studies and protocols, which relates back to the lack of (1) standardized stimulation parameters (intensity, frequency, duration of intervention), (2) knowledge of the optimal stimulation site and (3) the recruitment of large, well-characterized cohorts with a biomarker-confirmed diagnosis [33]. Due to these limitations, the FDA has not yet granted clearance for the commercial use of TMS devices in the treatment of AD pathology, as the amount of evidence collected so far is still not sufficient to clearly state its effectiveness at the clinical level [34].

To try to address some of these concerns, in the present study we conducted a meta-analysis of studies published in the last 10 years (2010–2021) aimed at disentangling the many protocols' characteristics that might have acted as modulating factors for the success of rTMS interventional outcomes in AD patients. To our knowledge, no study before 2010 has applied rTMS in AD patients with protocols relevant to our research question. Differently from prior recent published work [35–39], we were interested in investigating whether protocols that considered participants-specific neuroimaging scans for the selection of *individualized* stimulation targets held more successful outcomes compared to those relying on a *generalized* targeting selection criteria. Our initial hypothesis was that the personalization of the stimulation site at the participant level should ensure greater protocol efficacy, compared to interventions relying on a “one fits all” paradigm, whereby the same stimulation site, generally chosen based on gross anatomical landmarks (e.g. the “5 cm rule” [40] for the identification of the Dorsolateral Prefrontal Cortex—DLPFC), is targeted across patients regardless of their interindividual anatomical differences. Indeed, the wild intersubject variability in the structural and functional organization of the brain calls for the development of personalized stimulation approaches. This has become a debated topic in the emerging field of precision medicine, which aims at estimating quantitative models of brain functioning—and its alterations—through the combination of the individual biochemical, functional, metabolic, morphological and neuropsychological profile [41]. Despite encouraging results on the personalization of rTMS interventions in the treatment of depression [42–44], individualized patient care is a desirable, still unmet, need in AD [45]. Indeed, our literature search has highlighted the presence of few published article where the stimulation target was personalized based on the individual anatomy, but there is still a substantial lack of trials using more articulated patients' data, such as functional or tractography neuroimaging data. As a result, the level of personalization of the stimulation site might still have been suboptimal. Despite so, to our knowledge this is the first study trying to retrospectively investigate whether even a small degree of personalization could result in greater therapeutic responses compared to general targeting protocols.

On a second set of analyses, we compared additional protocol characteristics (i.e. different number of stimulation sites, pulse frequency, number of stimuli delivered, number of treatment sessions, concomitant cognitive training during stimulation) and participants' characteristics (e.g. educational level) to identify other factors that might modulate the success of high-frequency rTMS protocols in AD. Despite the fact that other neurostimulation interventions are routinely applied as an attempt to ameliorate AD symptomatology (e.g. transcranial electrical stimulation), TMS shows

the highest potential effectiveness [46]. For this reason, we decided to only review studies employing this methodology.

## Methods

### Search strategy and study selection

This study was designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [47]. A systematic literature search was performed from January 2010 to February 2021 in PubMed, PsycINFO and Scopus databases. The keywords used were: “TMS” or “Transcranial Magnetic Stimulation” and “AD” or “Alzheimer’s disease” and their combination. The focus was on original, randomized, double-blind clinical trials designed for therapeutic purposes, with either parallel or crossover designs. Review papers and the references cited in the identified studies were used to extend the search for further relevant literature. Only studies written in English were considered.

The following inclusion criteria were used to identify eligible studies: (1) AD diagnosis based on well-defined diagnostic criteria, such as the Diagnostic and Statistical Manual of Mental Disorders (DSM) or the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer Disease and Related Disorders Association (NINCDS/ADRDA) criteria; (2) Mild to Moderate AD as determined based on NINCDS-ADRDA criteria for probable AD or a Mini Mental State Examination (MMSE) score within the range of mild (21–26) or moderate (10–20) AD and/or a Clinical Dementia Rating scale (CDR) score of 1 or 2 [48]. If present, diagnosis severity based on laboratory results, such as computed tomography, magnetic resonance imaging, positron emission tomography or lumbar puncture, was also considered. To even-out study comparison, additional inclusion criteria were: (3) cognitive performance scores assessed via global cognitive scales—e.g. the MMSE and/or the Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog)—at both baseline (pre-treatment) and immediately post-treatment assessments; (4) the use of high-frequency ( $\geq 5$  Hz) rTMS protocols.

On the other hand, exclusion criteria included the following: (1) single-arm studies or studies without sham condition, to ensure control over placebo effects; (2) case reports, to ensure greater generalizability of the findings; (3) mixed-sample studies (severe AD or MCI patients)—unless patients’ data were reported separately for each severity group—since prior studies have shown greater effect of stimulation in milder patients [39, 49]; (4) AD patients with other concomitant forms of dementia (e.g. vascular dementia) or other comorbidities (e.g. depression) to ensure homogeneity across samples, as well as to

limit unwanted confounding factors; (5) 1 Hz rTMS, that is, inhibitory stimulation protocols, to further reduce the heterogeneity across studies, especially since they represent the minority of the interventions in AD studies; (6) theta-burst stimulation protocols, since their effects remain debated in the literature [50, 51]; and (7) absence of behavioural data relating to immediate post-treatment global cognitive scales, since our aim was to address immediate cognitive effects of stimulation. The detailed list of studies excluded from this meta-analysis and their reasons is available in Table S1 of the Supplementary Materials.


In this study, we chose to focus on high-frequency rTMS interventions in mild-to-moderate AD patients based on prior literature evidence suggesting higher improvement rate in these patients [31, 39, 52, 53]. The study selection process is briefly summarized in Fig. 1.

### Data extraction and statistical analysis

A total of 13 articles [54–66] were included in our meta-analysis, for an overall sample of 427 AD participants. A summary of the demographic and clinical information of each study is reported in Table 1. Details on the intervention parameters and efficacy of treatment are reported in Table 2.

The effectiveness of rTMS in AD patients was investigated by comparing the changes in global cognition at the administered cognitive scales (MMSE or ADAS-cog) between the active and sham groups/conditions. For each study considered in the analyses, we extracted the mean difference between the post- and pre-treatment global cognition scores for both the sham and active groups/conditions ( $M_1$  and  $M_2$ , respectively) as a measure of the rTMS-dependent change in global cognition. The corresponding standard deviations (SD) were also extracted when available; otherwise, they were calculated from the reported standard error of the mean (SE) and sample size ( $n$ ) according to the formula:  $SD = SE * \sqrt{n}$ . In the case of longitudinal studies with multiple time-points, the immediate post-treatment scores were selected and compared to pre-treatment baseline performance scores. In studies where both MMSE and ADAS-cog scores were reported, measures from the latter were preferred. Prior literature evidence has indeed compared the sensitivity across different global cognitive scales and highlighted more precise measuring by means of the ADAS-cog scale [67]. Unfortunately, it would have been advisable to use more sensitive cognitive scales to better understand the effect of rTMS on the specific cognitive domains, both as a function of disease stage and site of stimulation. Indeed, in the view of personalized approaches, the use of appropriate, sensitive and precise cognitive evaluations is at least as important as the accurate dosing of stimulation parameters. However, the majority of studies we analyzed did not report extensive cognitive evaluations, making it hard to compare

**Fig. 1** Diagram flow. Search strategy and study selection for the present meta-analytical study according to the PRISMA guidelines



studies on specific domains, but only at the global cognitive level.

The Meta-Essentials workbooks were used for the meta-analysis [68]. For each study considered in the analyses, the t-statistic for the comparison of the rTMS-dependent change in global cognition between the active and sham groups/conditions was used to derive the corresponding effect size (Hedge's  $g$ ) and its confidence interval. For the studies reporting the F-statistic, its square root was taken to compute the t-statistic. If the statistic for the active vs. sham comparison of the rTMS-dependent change in global cognition was not reported in the original study, the authors were kindly asked via email to provide it; alternatively, an approximation of the t-statistic was computed from the available data in the article, including the sample size, mean difference and standard deviation of the rTMS-dependent changes in global cognition in the active

and sham groups/conditions. The following formula was used for parallel trials:

$$t = \frac{M_2 - M_1}{SD_{\text{pooled}} * \sqrt{\frac{1}{n_1} + \frac{1}{n_2}}}$$

where  $M_1$  and  $M_2$  refer to the mean rTMS-dependent changes in global cognition of the sham and active group, respectively,  $n_1$  and  $n_2$  refer to their sample sizes, and  $SD_{\text{pooled}}$  refer to their pooled SD, computed based on the corresponding  $SD_1$  and  $SD_2$  according to the formula.

$$SD_{\text{pooled}} = \sqrt{\frac{(n_1 - 1)SD_1^2 + (n_2 - 1)SD_2^2}{n_1 + n_2 - 2}}$$

**Table 1** Demographic and Clinical Information

Study information		Sample size		Demographical information				Clinical information					
Authors	Study design	Experimental condition		Gender ratio (%Female)		Age		Education		Active AD Medications	Diagnostic criteria	Disease duration/stage	
		Active	Sham	Active	Sham	Active	Sham	Active	Sham			Active	Sham
Ahmed et al. [54]	Parallel	15	15	66.6%	66.6%	65.9±5.9	68.3±4.9	Literate ≤6 years 26.7% >6 years 20% Illiterate 53.3%	Literate ≤6 years 26.7% >6 years 20% Illiterate 53.3%	None for at least 2 weeks before	NINCDS-ADRDA	3.9±2.3/ mild-mod	4.4±2.5/ mild-mod
Bagattini et al. [55]	Parallel	12	12	41.67%	41.67%	73.56±4.91	73.35±1.09	7.5±3.75	7.33±2.42	ACHEI	Neurological examination	1.94±0.7/ mild-mod	1.67±1.3/ mild-mod
Brem et al. [56]	Parallel	16	8	75%	37.5%	69.25±6.80	67.50±10.27	14.25±4.64	17.50±4.00	ACHEI and/or Memantine	DSM-V NIA-AA	NA/ mild-mod	NA/ mild-mod
Cotelli et al. [57]	Parallel	5	5	NA	NA	71.2±6.1	74.4±3.8	6.4±1.3	4.8±0.4	ACHEI	NINCDS-ADRDA	NA/ moderate	NA/ moderate
Koch et al. [58]	Crossover	14	14	50%	50%	70.0±5.1	70.0±5.1	7.2±3.0	7.2±3.0	NA	CSF and MRI	1.15±0.43/ mild	1.15±0.43/ mild
Lee et al. [59]	Parallel	18	9	55.6%	62.5%	72.1±7.6	70.3±4.8	9.9±4.8	9.9±3.7	ACHEI	DSM-IV	NA/ mild-mod	NA/ mild-mod
Rabey et al. [60]	Parallel	7	8	71.43%	62.5%	72.6±8.9	75.4±9.07	NA	NA	ACHEI and/or Memantine	DSM-IV	NA/ mild-mod	NA/ mild-mod
Rutherford et al. [61]	Crossover	10	10	60%	60%	57–87	57–87	NA	NA	Stable dose for at least 3 months prior	Neurological examination	NA/ mild-mod	NA/ mild-mod
Sabbagh et al. [62]	Parallel	59	50	48.1%	42%	76.9	76.7	8th grade 5.1% High school 43% College 50.6% Other 1.3%	8th grade 8% High school 28% College 64% Other 0%	ACHEI and/or Memantine	DSM-IV	1.7/ mild-mod	1.8/ mild-mod
Wu et al. [63]	Parallel	26	26	62%	58%	71.4±4.8	71.9±4.8	11.4±2.7	11.5±2.1	ACHEI	NINCDS-ADRDA	5.1±1.5/ moderate	5.1±1.5/ moderate
Xingxing et al. [64]	Parallel	37	38	35.95%	36.84%	65.97±8.47	64.58±7.88	5.65±3.21	6.75±4.51	ACHEI	DSM-V	3.7±1.75/ mild-mod	3.97±1.62/ mild-mod
Zhang et al. [65]	Parallel	15	13	80%	77%	69.00±8.19	68.54±7.93	12.40±2.06	11.85±2.38	Memantine	NINCDS-ADRDA+MRI	NA/ mild-mod	NA/ mild-mod
Zhao et al. [66]	Parallel	17	13	58.8%	54.8%	69.3±5.8	71.4±5.2	4.8±1.9	4.9±3.5	ACHEI	DSM-IV	NA/ mild-mod	NA/ mild-mod

A summary of the main AD sample characteristics is reported for each study, including mean age, gender ratio, years of education, ongoing medical treatments at the time of stimulation and years of disease duration when available

ACHEI acetylcholinesterase inhibitor, DSM Diagnostic and Statistical Manual of Mental Disorders, NINCDS-ADRDA National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer disease and Related Disorders Association, CSF cerebrospinal fluid (lumbar puncture), MRI magnetic resonance imaging, NA not available/not reported information

For crossover trials, the t-statistic was computed as the standardized mean difference ( $M_{\text{diff}}$ ) of the mean rTMS-dependent changes in global cognition in the sham and active conditions according to the formula:

$$t = \sqrt{n} \frac{M_{\text{diff}}}{SD_{\text{diff}}},$$

where  $SD_{\text{diff}}$  is the standard deviation of the differences of the mean rTMS-dependent changes in global cognition in the sham and active conditions.

The Cohen's  $d$  effect size was then computed for each study according to the formula

$$d = t \sqrt{\frac{1}{n_1} + \frac{1}{n_2}},$$

for parallel trials and the formula

$$d = \frac{t}{\sqrt{n}},$$

for crossover trials.

Finally, the Hedges'  $g$  effect size was computed as:

$$g = d \left( 1 - \frac{3}{4(n_1 + n_2) - 9} \right).$$

Heterogeneity across studies was estimated based on the Cochrane's  $Q$ ,  $I^2$ , and  $T^2$ , which reflect, respectively, the variability of the effects around the weighted average effect, the proportion of observed variance reflecting real differences in effect size and an estimate of the variance of the true effect size [69]. Random effects model with 95% confidence interval was run to summarize the effect size, as well as to test for differences between studies' groups in our subgroup analyses (see next paragraphs).

Finally, to represent the risk of publication bias, funnel plots were created in Meta-Essentials [68] and the resultant effect sizes adjusted by means of the trim-and-fill procedure [70].

### Moderator analysis

A moderator analysis (meta-regression) was conducted to test the effect that the total number of stimulation pulses had on the effect size of the considered studies. This predictor was obtained by multiplying the number of pulses per session by the number of total sessions in the study protocol.

### Subgroup analyses

In our main hypothesis, we speculated that interventions where the stimulation site is *individualized* based on the

participant's neuroimaging data would result in greater stimulation effects compared to interventions relying on a *generalized* target selection procedure, where general anatomical landmarks are used to approximately identify the same stimulation site across participants (e.g. studies relying on the electroencephalography (EEG) 10–20 electrode cap disposition or the "5 cm rule" to determine the position of the DLPFC). Indeed, recent efforts in the direction of personalized interventions in the treatment of depression have been proven successful [42–44]. However, to our knowledge, no such investigation has yet being carried out in the field of AD research. Given the purpose of this study, additional subgroup comparisons were then carried out in order to understand the role that several other variables, related to both the experimental protocol and the sample characteristics, might have had in modulating the effectiveness of the treatment, as suggested by a recent meta-analysis [39]. In particular, we compared the efficacy of studies stimulating: (i)  $\leq 10$  Hz versus  $> 10$  Hz frequency; (ii) a single region (DLPFC) versus multiple brain regions stimulated sequentially; (iii) patients with low versus high education ( $> 8$  years of education); (iv) the presence of concomitant cognitive training or not.

Analysis of variance (ANOVA) models were then run to test for significant differences in the effect sizes between groups of studies.

### Quality assessment

The methodological quality of 11, out of 13, parallel, double-blind, randomized clinical trials included in the meta-analyses was evaluated by two authors independently (LD, AM) with the Cochrane Risk of Bias tool (RoB2) for randomized trials [71]. The risk of bias scale covers five domains of bias: randomisation process (D1), deviations from the intended intervention (D2), missing outcome data (D3), measurement of the outcome (D4), selection of the reported results (D5). The remaining assessment of the two crossover, double-blind, randomized trials was carried out by the same two authors (LD, AM) by means of the RoB2 tool for crossover trials. In addition to the above-mentioned domains, this scale also investigates the bias arising from period and carryover effects (DS). In case of conflicting judgments, a third author's (EA) opinion was asked.

## Results

### Efficacy of high-frequency stimulation in AD

The pooled results of the 13 studies included in our study indicated that rTMS could significantly improve participants' global cognitive functioning as evidenced by an increase in the MMSE scores, or a decrease in the ADAS-Cog scores

**Table 2** rTMS intervention details

Study information	TMS parameters				General cognition			Results		
	Study design	Frequency	Intensity	Stimulation site	Target	Pulses	Screening test		Mean $\pm$ SD	
									Baseline	After rTMS
Ahmed et al. [54]	rTMS	20 Hz	90% RMT	R-DLPFC; L-DLPFC	GEN	2000pulses $\times$ 5 sessions	MMSE	18.4 $\pm$ 2.7	21.4 $\pm$ 3.2	Five daily sessions of 20 Hz rTMS on L-DLPFC and r-DLPFC lead to overall cognitive improvement in patients with mild to moderate AD, which was maintained for 3 months
Bagattini et al. [55]	rTMS + CT	20 Hz	100% RMT	L-DLPFC	GEN	2000pulses $\times$ 20 sessions	MMSE	21.62 $\pm$ 2.61	22.45 $\pm$ 1.89	The improvement in trained associative memory induced with rTMS is superior to CT alone, with less compromised and more educated patients showing greater benefit
Brem et al. [56]	rTMS + CT	10 Hz	120% RMT	L/R-IFG, L/R-STG, L/R-DLPFC	IND	1300pulses $\times$ 30 sessions	ADAS-Cog	$\Delta M = -2.18$ $S_{diff} = 3.7$		Combinatory treatment of rTMS and CT leads to significant cognitive improvement. Baseline TMS-induced plasticity is predictive of post-intervention changes in cognition
Cotelli et al. [57]	rTMS	20 Hz	100% RMT	L-DLPFC	GEN	2000pulses $\times$ 20 sessions	MMSE	16.2 $\pm$ 2.7	16.0 $\pm$ 3.3	Beneficial effects of rTMS on sentence comprehension in AD patients. No significant differences are found for other cognitive domains

Table 2 (continued)

Study information		TMS parameters			General cognition			Results		
Authors	Study design	Frequency	Intensity	Stimulation site	Target	Pulses	Screening test	Main findings		
							Mean $\pm$ SD			
							Baseline	After rTMS		
Koch et al. [58]	rTMS	20 Hz	100% RMT	PRECUNEUS	IND	1600pulses $\times$ 30 sessions	MMSE	26.9 $\pm$ 1.9	27.3 $\pm$ 1.6	rTMS induces a selective improvement in episodic memory, but not in other cognitive domains. This improvement is accompanied by modulation of brain connectivity
Lee et al. [59]	rTMS + CT	10 Hz	90–110% RMT	Broca, Wernicke L/R- DLPFC, L/R- pSAC	IND	1200pulses $\times$ 30 sessions	ADAS-Cog	23.61 $\pm$ 6.40	19.33 $\pm$ 8.30	rTMS combined with CT represents a useful adjuvant therapy with cholinesterase inhibitors, particularly during the mild stage of AD and concerning memory and language domains
Rabey et al. [60]	rTMS + CT	10 Hz	90–110% RMT	Broca, Wernicke L/R- DLPFC, L/R- pSAC	IND	1300pulses $\times$ 54 sessions	ADAS-Cog	$\Delta M = -3.76$ $S_{diff} = 3.49$	rTMS combined with CT provides a significant improvement in the mean ADAS-cog score and this improvement is greater than that achievable by using CT or TMS treatment alone	
Rutherford et al. (2015)	rTMS	20 Hz	90–100% RMT	L/R-DLPFC	GEN	2000pulses $\times$ 13 sessions	ADAS-Cog	$\Delta M = -4.00$ $S_{diff} = 3.95$	General cognitive skills improve, but the effect may not last longer than a week or two. A significant effect is seen in the MoCA scores, but not as much in the ADAS-cog scores	



**Table 2** (continued)

Study information	TMS parameters				General cognition			Results			
	Authors	Study design	Frequency	Intensity	Stimulation site	Target	Pulses		Screening test	Mean ± SD	
										Baseline	After rTMS
Sabbagh et al. [61]	rTMS+CT	10 Hz	110% RMT	Broca, Wernicke L/R-DLPFC, L/R-pSAC	IND	1300pulses × 30 sessions	ADAS-Cog	ADAS-Cog	$\Delta M = -0.706$ $S_{diff} = 3.642$	No statistically significant difference on ADAS-Cog between active and sham groups is found at the end of treatment. At follow up (5 months) only the active group shows a sustained improvement	
Wu et al. [63]	rTMS	20 Hz	80% RMT	L-DLPFC	GEN	1200pulses × 20 sessions	ADAS-Cog	ADAS-Cog	$30.08 \pm 6.07$ $24.16 \pm 5.21$	Combining drugs with rTMS adjunct treatment significantly improves both cognitive functioning and the behavioural and psychological symptoms of AD	
Xingxing et al. [64]	rTMS	20 Hz	100% RMT	L-DLPFC	GEN	2000pulses × 30 sessions	ADAS-Cog	ADAS-Cog	$29.12 \pm 5.97$ $26.23 \pm 6.01$	Small but significant improvement after rTMS treatment is reported compared with sham. Cortical LTP-like plasticity could predict treatment responses of cognitive improvements in AD	
Zhang et al. [65]	rTMS+CT	10 Hz	90% RMT	L-DLPFC; L-LTL	GEN	1000pulses × 20 sessions	MMSE	MMSE	$\Delta M = 3.27$ $S_{diff} = 2.169$	rTMS combined with CT improves cognitive function and ameliorates agitation and apathy in patients with mild and moderate AD by increasing the NAA/Cr metabolites ratio in the L-DLPFC	

Table 2 (continued)

Study information	TMS parameters			General cognition		Results						
	Authors	Study design	Frequency	Intensity	Stimulation site		Target	Pulses	Screening test	Mean ± SD	After rTMS	Main findings
Zhao et al. [66]	rTMS	20 Hz	90% RMT	Parietal P3/P4 Posterior-temporal T5/T6	GEN	1000pulses × 20 sessions	ADAS-Cog	22.6 ± 5.9	18.5 ± 5.4	Patients in the active group significantly improve from baseline after 6 weeks of intervention. Improvement in episodic memory and language was higher in the mild AD group, compared to the moderate AD group		

A summary of the main rTMS parameters used in each study is reported, including cognitive scores at the global cognitive scales before and immediately after the intervention. A brief summary of the main findings is also provided for each study

CT cognitive training, RMT resting motor threshold, L left, R right, DLPFC dorsolateral prefrontal cortex, IFG inferior frontal gyrus, STG superior temporal gyrus, pSAC parietal Somatosensory Association Cortices, LTL lateral temporal lobe, GEN generalized targeting, IND individualized targeting, MMSE Mini-Mental State Examination, ADAS-Cog Alzheimer's Disease Assessment Scale (Cognitive Subscale),  $\Delta M$  mean difference,  $S_{diff}$  pooled standard deviation

(Hedges'  $g = 0.59$ ,  $SD = 0.15$ ;  $CI = 0.27-0.91$ ,  $p < 0.001$ ) in the random effects model analysis, showing a moderate heterogeneity ( $p_Q = 0.009$ ;  $I^2 = 54.88\%$ ,  $T^2 = 0.16$ ). Figure 2 reports the effect sizes of the single studies, as well as the combined effect size, in form of a forest plot.

### Subgroups analyses

In contrast to our main hypothesis, the subgroup analysis comparing the efficacy of studies employing *individualized* ( $n = 5$ , Hedges'  $g = 0.34$ ;  $CI = -0.10-0.77$ ,  $I^2 = 39.36\%$ ,  $p_Q = 0.159$ ,  $T^2 = 0.09$ ) versus *generalized* ( $n = 8$ , Hedges'  $g = 0.75$ ;  $CI = 0.39-1.11$ ,  $I^2 = 45.72\%$ ,  $p_Q = 0.075$ ,  $T^2 = 0.12$ ) targeting (Fig. 3) did not show a significant difference ( $p = 0.146$ ).

Additional analyses aimed at understanding which stimulation factors might have an impact on rTMS efficacy in AD also did not show any statistically significant difference. In particular, at the protocol level, stimulation of the left DLPFC ( $n = 4$ , Hedges'  $g = 0.73$ ;  $CI = -0.07-1.40$ ,  $I^2 = 69.33\%$ ,  $p_Q = 0.021$ ,  $T^2 = 0.27$ ) versus stimulation of multiple sites ( $n = 8$ , Hedges'  $g = 0.55$ ;  $CI = -0.27-0.84$ ,  $I^2 = 18.99\%$ ,  $p_Q = 0.279$ ,  $i^2 = 0.03$ ) did not impact the results ( $p = 0.614$ ) (Fig. 4, panel A). Furthermore, the efficacy of studies where the stimulation frequency was  $\leq 10$  Hz ( $n = 5$ , Hedges'  $g = 0.62$ ;  $CI = -0.21-1.02$ ,  $I^2 = 45.11\%$ ,  $p_Q = 0.121$ ,  $T^2 = 0.11$ ), compared to those with stimulation frequency  $> 10$  Hz ( $n = 8$ , Hedges'  $g = 0.55$ ;  $CI = -0.14-0.97$ ,  $I^2 = 62.55\%$ ,  $p_Q = 0.009$ ,  $T^2 = 0.23$ ) did not show any significant difference ( $p = 0.837$ ) (Fig. 4, panel B). At the sample level, studies in which participants received both cognitive training and stimulation ( $n = 6$ , Hedges'  $g = 0.52$ ;  $CI = 0.15-0.89$ ,  $I^2 = 38.12\%$ ,  $p_Q = 0.152$ ,  $T^2 = 0.09$ ), compared to those receiving stimulation alone ( $n = 7$ , Hedges'  $g = 0.62$ ;  $CI = 0.16-1.07$ ,  $I^2 = 63.92\%$ ,  $p_Q = 0.011$ ,  $T^2 = 0.24$ ), did not show any significant difference ( $p = 0.764$ ) (Fig. 4, panel C). Similarly, no difference in the efficacy of stimulation was observed between studies in which participants had a high ( $n = 5$ , Hedges'  $g = 0.78$ ;  $CI = 0.28-1.28$ ,  $I^2 = 73.58\%$ ,  $p_Q = 0.004$ ,  $T^2 = 0.31$ ) and low ( $n = 6$ , Hedges'  $g = 0.39$ ;  $CI = -0.00-0.79$ ,  $I^2 = 47.46\%$ ,  $p_Q = 0.090$ ,  $T^2 = 0.12$ ) level of education ( $p = 0.287$ ) (Fig. 4, panel D).

### Moderator analysis

The moderator analysis revealed a significant correlation between the total number of pulses delivered per protocol and the study effect size ( $\beta = 0.54$ ,  $p = 0.038$ ,  $R^2 = 29.16\%$ ) (Fig. 5), with the following regression equation:  $g = 0.0474 + Pulses * 1.38 * 10^{-5}$ , where *Pulses* indicates the total number of pulses delivered. Based on this analysis, approximately 39,000 pulses are needed to have an effect

size of  $g=0.59$ , equivalent to the pooled effect size we found.

### Risk of bias analyses

As shown in Fig. 6, the funnel plot is visually symmetrical at the Begg & Mazumdar's test ( $p=0.807$ ), as well as the Egger's test ( $p=0.981$ ), thus suggesting that no significant publication bias was present in the selected studies. As a result, no fill-and-trim procedure was carried out to adjust the effect sizes.

In addition, each study was evaluated on the risk of bias across 5 domains, proving an overall low to moderate risk (Table 3).


### Discussion

Repetitive TMS is a safe and promising noninvasive intervention for a variety of neuropsychiatric conditions [72, 73]. However, the most recent evidence-based guidelines on the therapeutic use of rTMS have shown debating results for its use in the management of the AD pathology, reaching only a level C evidence (“possibly effective or ineffective”) [31]. Several factors might have led to this conclusion, especially since the high heterogeneity in the administered protocols makes it hard to compare across studies [33].

The main aim of our study was that of addressing which protocols' characteristics are more likely to explain the heterogeneity in the results across studies. To do so, we started by investigating the importance that personalized stimulation target selection might have in AD studies employing rTMS to boost or preserve residual cognitive functioning. The rationale for personalized care is not new in the neuroscience field and rather stands from the need to develop in-person care via the use of therapies that are biomarker-guided and grounded on the biological characteristics of the individual patient [74–76]. In the clinical management of the AD pathology, progress in this direction has been made with the






establishment of the Alzheimer Precision Medicine Initiative (APMI), which aims at estimating quantitative models of the disease through the combination of the individual biochemical, functional, metabolic, morphological and neuropsychological profile [41]. As for what concerns the personalization of rTMS interventions, this has also been of interest in recent literature studies. For example, in the year 2020 alone, several applications of rTMS in the management of depression have reported benefits following individualized target selection. Interestingly, personalization of the stimulation site has been achieved through a variety of approaches, including (i) the identification of the target site based on a localization of circuits and the corresponding scalp targets that relate to post-TMS improvement in depressive symptoms—the so-called symptom-response map—[44]; (ii) the targeting of functionally derived individual brain parcels [43]; or (iii) based on the individual connectivity profile of small regions of interest in the treated pathology, such as the subgenual cingulate cortex [42]. Given the high relevance of such recent discoveries and the interest for the same principles to be applied in the management of the AD pathology [45], we were interested in determining whether similar favourable results could be observed by retrospectively looking at the effect size of studies employing individual data for the selection of the stimulation site. In this regard, our study confirmed prior literature evidence on the efficacy of rTMS interventions in AD patients [33, 35, 37, 38, 49, 52, 77, 78], but we were not able to demonstrate that personalized interventions held better outcomes than those employing more general targeting approaches. One possible explanation is that studies individualizing the stimulation site relied on patients' anatomical magnetic resonance imaging, but not on their functional or structural connectivity profile. This might have led to a smaller degree of individualization, not capable of detecting neural re-arrangements typical of the pathological aging brain. Indeed, although individual brains vary substantially in their cytoarchitectonic and macrostructural anatomy, they also do so in their functional organization with respect to the structural anatomy [79–81]. In

**Fig. 2** Forest plot. Effect sizes of individual studies and of their pooled effect (bottom row) are reported. Meta-analytic evidence suggests a favourable effect of rTMS in the amelioration of global cognitive functioning in mild–moderate AD patients. Dots' size represents the relative weight of each study



**Fig. 3** Forest plots of individualized vs generalized target selection subgroup analyses. No significant differences could be observed in the effect sizes of studies as a function of target selection procedure

*Generalized vs Individualized Targeting*



**Fig. 4** Forest plots of subgroup analyses. No significant differences could be observed in the effect sizes of studies as a function of: number of stimulation sites (L-DLPFC vs multiple sites) (A), frequency


of stimulation ( $\leq 10$  Hz vs  $> 10$  Hz) (B), TMS only or TMS combined with cognitive training (CT) (C), high ( $> 8$ ) vs low ( $\leq 8$ ) patients' education level (D)

particular, functional connectivity profiles are characterized by stable individual features, with modest variations from task-state and day-to-day variability [82], as well as great individual specificity [83], making them desirable features


to be accounted for when aiming at the individualization of stimulation sites. In principle, indeed, precise targeting of individual-specific functional brain networks should improve the efficacy of NIBS interventions [84]. Similarly,

recent evidence has shown that the structural connectivity profile is a good predictor of the propagation of the TMS signal [85], with possible implications in its use as a variable of interest in stimulation target definition. We might hence argue that past effort in the individualization of stimulation sites has not been of sufficient extent. Future interventions will need to move beyond the use of simple anatomical data and rather consider functional and structural connectivity profiles for a better characterization of the individual brain organization and of its targeting.

Nevertheless, even when other variables related to the experimental protocol and the sample characteristics were compared (i.e. differences in stimulation frequency, targeting of single or multiple stimulation sites, the education level or the additive effect of concurrent cognitive training), no significant differences were detected across studies employing different combinations of these factors. Of interest, prior work had instead highlighted meaningful differences in this direction, showing significantly greater cognitive improvement in participants with a high level of education, who received rTMS treatment at multiple stimulation sites, for more than 10 sessions, at 20 Hz instead of lower frequencies and that possibly received simultaneous cognitive training [39]. However, the different statistical models used to compare effect sizes in our work compared to prior published work, may explain the conflicting results. In fact, in the work of Wang and colleagues, when the heterogeneity value  $I^2$  was  $< 50\%$ , a fixed effects model was applied, in contrast to our choice to always apply a random effects model. This methodological choice was made on the basis of a couple of reasons. First, there were insufficient good reasons to believe that all studies were functionally identical [86]: given the widespread clinical and/or methodological differences found in the included



**Fig. 5** Moderator analysis. Linear regression analyses revealed a significant correlation between the total number of pulses per protocol and the studies' effect size. Dots' size is indicative of each study relative weight






**Fig. 6** Funnel plot for Publication Bias analysis. Standard errors and effect sizes of the included studies are shown in the funnel plot. No significant publication bias was detected

studies, statistical heterogeneity was inevitable [87]. Second, being the aim of a meta-analysis that of including independent research studies, the hypothesis of a common effect size was not tenable [88]. Indeed, a fixed effects model requires the assumption of a common effect size, which can lead to the lack of generalizability outside the well-defined population included in the analysis [86]. Furthermore, the use of a fixed effects model in the presence of heterogeneity could lead to an underestimation of the variability of the treatment and a consequent deviation from the true conclusions of the study [89]. In light of this, a random approach analysis seemed to be more appropriate in order to quantify the heterogeneity of the effects across studies, to be able to incorporate this variation in the confidence intervals of the data distribution, to test the adequacy of the models that attempt to explain this variation, and overall to obtain accurate effect size estimates for each study [90].

On the other hand, we were able to replicate the positive association between the total number of pulses delivered per protocol and studies' effect size in our moderator analysis. Indeed, the periodic repetition of rTMS stimulation, usually administered on a daily basis (within 24 h from the previous session), can lead to cumulative plastic changes that can generate long-lasting neuromodulatory effects [30], on top of the 30–60 min after-effects observed following a single stimulation [91]. However, it is important to consider that the total number of pulses was treated as a collective measure (number of pulses per session by the number of total sessions in the study protocol), and that we did not consider the sparseness of pulses distribution throughout the protocol.

**Table 3** Risk of bias

Study	Weight	D1	DS	D2	D3	D4	D5	Overall
Ahmed (2012)	6,71%	+		+	+	+	!	+
Bagattini (2020)	7,60%	+		+	+	+	!	+
Brem (2020)	6,91%	+		+	+	+	!	+
Cotelli (2011)	4,93%	+		+	+	+	!	+
Koch (2018)	8,12%	+	+	+	+	+	!	!
Lee (2016)	7,18%	+		+	+	+	!	+
Rabey (2012)	5,47%	+		+	+	+	!	!
Rutherford (2015)	5,29%	+	+	!	!	+	!	!
Sabbagh (2019)	11,54%	+		+	+	+	!	!
Wu (2015)	9,37%	+		+	+	+	!	+
Li (2021)	11,03%	+		+	+	+	!	+
Zhang (2019)	7,56%	+		+	+	+	!	+
Zhao (2017)	8,28%	+		+	+	+	!	+

 Low risk  
 Some concerns  
 High risk

Each study was evaluated based on the RoB2 tool for the assessment of the risk of bias across 5 domains: randomisation process (D1), deviations from the intended intervention (D2), missing outcome data (D3), measurement of the outcome (D4), selection of the reported result (D5). In addition, for the 2 studies with a crossover design, the bias arising from period and carryover effects (DS) was also assessed. The overall column refers to the overall quality of the study, considering the average across the single domains

In this sense, past studies have highlighted more favourable cognitive outcomes in patients receiving at least 10 stimulation sessions [39]. Only recently, systematic studies have been carried out to determine the impact of different number of pulses in remission rates from major depressive disorder, with inconclusive results [92]. In regard of the AD pathology, it would be of interest for future studies to better characterize such dosing parameters, in terms of the relationship between pulses and sessions.

## Limitations

Based on our present findings, several considerations need to be made. First of all, our analyses might have suffered from a somehow limited amount of placebo-controlled trials and the often limited number of study participants. Indeed, our initial literature search identified 18 studies in which AD patients received rTMS treatment; of those, only 13 were included in the analyses as 5 of them lacked the presence of a control group (see Fig. 1). Secondly, we observed that the included studies in this meta-analysis had relatively small sample sizes, as demonstrated by the fact that 10 out of the 13 studies considered have a sample size of less than, or equal to, 30 participants (including 3 studies with less than 20 participants), which might have also undermined the possibility of adequate and in-depth statistical analysis.

Finally, as already stressed in the past, there is substantial heterogeneity across studies in terms of the rTMS

parameters, sites of stimulation and samples' characteristics [33], making it hard to conduct clear-cut subgroup analyses. Beyond this, there are several other criticalities related to rTMS interventions in a broader sense. In particular, several intrinsic factors to the stimulation can result in inter-subject variability, contributing to the heterogeneity of the results. Some of these factors include: (1) participants' age and gender, (2) the distance between the scalp and the cerebral cortex in modulating the amount of current that reaches the brain tissue, (3) the richness and integrity of the white matter tracts underlying the stimulation site and finally (4) genetic phenotypes [30, 93]. In this regard, it has been shown that the modulatory effect of TMS is reduced in participants carrying the "Val66Met" allele of the brain-derived neurotrophic factor gene (BDNF) [94]. When applied to the AD population, these limitations are further worsened by other factors, such as the lack of well-defined diagnostic criteria, as AD patients are mostly identified based on probable diagnoses in the absence of appropriate disease biomarkers (e.g. positron emission tomography-derived amyloidosis and tau maps [95], lumbar puncture) and the even greater scalp-to-cortex distance due to the widespread cortical atrophy [96]. Furthermore, we observed significant heterogeneity in the neuropsychological batteries employed to measure patients' cognitive functioning. The majority of the studies relies on global cognitive scales (such as the MMSE and the ADAS-Cog) which, although useful, might lack sufficient sensitivity to adequately monitor patients' improvement over time. Although some of the included studies reported

information related to single cognitive domains, the lack of coherent assessment protocols makes it hard to conduct a meta-analysis on the effect of rTMS in specific cognitive functions, such as episodic memory abilities or visuo-spatial orientation, as those are among the first functions affected by the disease [6].

Despite the aforementioned limits, few precautionary measures can be taken in trying to overcome them. For example, to control for the induced electrical currents in patients with diffuse atrophic patterns, multi-scale computational approaches can be used to model the induced TMS activation in the underlying neural substrates [97]. The use of head models allows to represent the type of activated neural elements, the spatial extent of such activations, and how spatial and temporal parameters of TMS determine threshold and site of activation, particularly when considering the complicated and subject-dependent human brain geometry [98, 99]. Indeed, various studies have investigated the inter-subject variability of the TMS-induced electric field and have shown consensus that both the strength of the electric field and the location of the hot spot depend on individual anatomical differences [100, 101].

Secondly, future studies may make use of a deeper understanding of the individual network topology to guide stimulation interventions. One example is represented by studies directed at targeting individual-specific “hub” brain areas, based on the assumption that modulation of highly connected regions should have greater impact on cognition than nonhub brain areas. Indeed, regions that connect to several other networks, known as connector hubs, are believed to be crucial for information transfer and between-network communication within the brain [102]. In line with this assumption, a recent study reported that the inhibition of a hub via its TMS stimulation interrupted information processing during working memory tasks with a substantial difference with respect to when a nonhub site was targeted instead, despite both targets being separated by only few centimetres along the right middle frontal gyrus [103]. As stated by the authors, such findings further stress the notion that individual-specific network features are functionally relevant and could be used in principle as stimulation sites in future TMS interventions. Indeed, the use of network-guided TMS has long been suggested in the literature, based on the notion that different network alteration profiles can be appreciated across neurological disorders [78, 104]. Based on this rationale, several studies have highlighted the possibility to act on those alterations in trying to restore healthy brain network patterns [45, 105], whereby brain networks are employed for both the definition of the target and for the monitoring of the efficacy of the stimulation treatment [106].

Finally, numerous studies have assessed the relationship between the ongoing oscillatory activity of the brain (as measured via EEG) and the physiological responses to

TMS. General TMS devices do not adjust the output stimulation based on the real-time brain activity information, despite recent evidence that the ongoing oscillatory activity of the brain, especially its phase, may affect stimulation effects [107, 108]. The automatic electronic adjustment of the stimulation based on previous responses, also known as closed-loop stimulation, is widely employed in other neuromodulation approaches, such as transcranial alternating current stimulation (tACS), which specifically aims at the entrainment of the underlying brain physiological activity. The main rationale stands from the notion that neurons are more likely to fire in correspondence to a specific time point in their spiking cycle, such as that the closer the stimulation is delivered to that narrow time window, the greater the likelihood of synaptic strengthening or weakening [109]. However, current results remain controversial, as many studies have reported offline effects that are independent from oscillatory entrainment mechanisms and rather reflect more general changes in plasticity, thus not specific to the stimulation been tuned to the underlying neural firing [109]. Still, it would be desirable for future studies to try to adapt similar closed-loop procedures for the fine tuning of the frequency at which rTMS is delivered based on the ongoing underlying brain activity. Indeed, recent evidence suggests that stimulation based on real-time knowledge of the state of activity of the brain (for example represented by the sinusoidal oscillation of a specific frequency band) can help control the efficacy of the induced plasticity changes and induce more specific neuromodulatory effects [110, 111].

## Conclusion

This study shows that rTMS is a promising intervention in the treatment of patients with mild to moderate AD and highlights the positive correlation between effect size reported in the reviewed studies and the total number of pulses administered during the intervention. Further investigations will be necessary to better clarify which combinations of protocol characteristics and parameters are most efficient in promoting residual cognitive functioning in AD patients. Of outermost importance is the development of standardized approaches to reduce inter-study heterogeneity and foster reliable findings. Future rTMS protocols in the AD population would benefit from: (1) an in-depth and biomarker-guided diagnostic framework, (2) stimulation target selection that takes into account individual differences in the underlying anatomical, structural/functional connectivity and oscillatory activity patterns and finally (3) the consistent use of neuropsychological test batteries for the comparable measurement and monitoring of patients' cognitive functioning across studies. Finally, it would be desirable to better assess the long-term efficacy of repeated

rTMS interventions, as follow-up timing is also highly variable between studies.

Given the complex and multifactorial nature of the AD pathology, multidisciplinary efforts are needed in order to integrate inter-individual variability as part of the foundation of the intervention strategy, rather than examining it strictly post hoc as a mere confounding variable. Practical examples include the development of personalized stimulation protocols through a multiscale approach and based on the individual clinical make-up. In this sense, models could be constructed integrating knowledge on the cellular to large-scale networks alterations (including functional and structural connectome organization) of the individual patients to personalize stimulation in at least three of its parameters: site selection, intensity and frequency of stimulation. This would greatly help ensuring that the most critical region is reached by electrical currents strong enough to modulate remaining synaptic plasticity mechanisms.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s00415-022-11236-2>.

**Author contributions** All authors contributed to the conceptualization and methodology of the study. LD and AM performed the literature search and wrote the original draft. LD, AM and Ettore Ambrosini conducted the formal analyses of this paper. EA and AV supervised the study. All authors reviewed and edited the manuscript throughout the process for critical content.

**Funding** Open access funding provided by Università degli Studi di Padova within the CRUI-CARE Agreement. This work was supported by the “Department of excellence 2018–2022” initiative of the Italian Ministry of education (MIUR) awarded to the Department of Neuroscience—University of Padua and Ricerca Finalizzata 2018—Young Researchers Grant of the Italian Ministry of Health to Francesca Burgio and Antonino Vallesi (GR-2018-12367927).

## Declarations

**Conflict of interest** The authors report no conflict of interest.

**Ethical approval** All studies reported in this review were approved by their local ethics committee and were hence conducted in accordance with the Declaration of Helsinki and its later amendments.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Alzheimer's Association (2021) Facts and figures. In: *Alzheimer's Dis. Dement.* <https://www.alz.org/alzheimers-dementia/facts-figures>. Accessed 8 Jun 2021
2. Patterson C (2018) The state of the art of dementia research: New frontier. *World Alzheimer's Report 2018.* <https://apo.org.au/node/260056>
3. Buckner RL, Snyder AZ, Shannon BJ et al (2005) Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. *J Neurosci* 25:7709. <https://doi.org/10.1523/JNEUROSCI.2177-05.2005>
4. McDonald CR, McEvoy LK, Gharapetian L et al (2009) Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. *Neurology* 73:457. <https://doi.org/10.1212/WNL.0b013e3181b16431>
5. Pini L, Wennberg AM, Salvalaggio A et al (2021) Breakdown of specific functional brain networks in clinical variants of Alzheimer's disease. *Ageing Res Rev* 72:101482. <https://doi.org/10.1016/j.arr.2021.101482>
6. Sheppard O, Coleman M (2020) Alzheimer's disease: etiology, neuropathology and pathogenesis. Exon Publications
7. Frisoni GB, Ritchie C, Carrera E et al (2019) Re-aligning scientific and lay narratives of Alzheimer's disease. *Lancet Neurol* 18:918–919. [https://doi.org/10.1016/S1474-4422\(19\)30323-0](https://doi.org/10.1016/S1474-4422(19)30323-0)
8. Jack JR, Bennett DA, Blennow K et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's Dement* 14:535–562. <https://doi.org/10.1016/j.jalz.2018.02.018>
9. Scheltens P, Blennow K, Breteler MMB et al (2016) Alzheimer's disease. *The Lancet* 388:505–517. [https://doi.org/10.1016/S0140-6736\(15\)01124-1](https://doi.org/10.1016/S0140-6736(15)01124-1)
10. Armstrong RA (2019) Risk factors for Alzheimer's disease. *Folia Neuropathol* 57:87–105. <https://doi.org/10.5114/fn.2019.85929>
11. Kim J, Woo S-Y, Kim S et al (2021) Differential effects of risk factors on the cognitive trajectory of early- and late-onset Alzheimer's disease. *Alzheimer's Res Ther.* <https://doi.org/10.1186/s13195-021-00857-w>
12. Lee W-J, Liao Y-C, Wang Y-F et al (2020) Summative effects of vascular risk factors on the progression of Alzheimer disease. *J Am Geriatr Soc* 68:129–136. <https://doi.org/10.1111/jgs.16181>
13. Ojo JO, Reed JM, Crynen G et al (2021) APOE genotype dependent molecular abnormalities in the cerebrovasculature of Alzheimer's disease and age-matched non-demented brains. *Mol Brain.* <https://doi.org/10.1186/s13041-021-00803-9>
14. Szczechowiak K, Diniz BS, Leszek J (2019) Diet and Alzheimer's dementia—nutritional approach to modulate inflammation. *Pharmacol Biochem Behav* 184:172743
15. Veurink G, Perry G, Singh SK (2020) Role of antioxidants and a nutrient rich diet in Alzheimer's disease. *Open Biol.* <https://doi.org/10.1098/rsob.200084>
16. Bhatti GK, Reddy AP, Reddy PH, Bhatti JS (2020) Lifestyle modifications and nutritional interventions in aging-associated cognitive decline and Alzheimer's disease. *Front Aging Neurosci.* <https://doi.org/10.3389/fnagi.2019.00369>
17. Valenzuela PL, Castillo-García A, Morales JS et al (2020) Exercise benefits on Alzheimer's disease: state-of-the-science. *Ageing Res Rev* 62:101108. <https://doi.org/10.1016/j.arr.2020.101108>
18. Bellou V, Belbasis L, Tzoulaki I et al (2016) Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and



- meta-analyses. *Alzheimer's Dementia*. <https://doi.org/10.1016/j.jalz.2016.07.152>
19. Livingston G, Huntley J, Sommerlad A et al (2020) Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *The Lancet* 396:413–446. [https://doi.org/10.1016/S0140-6736\(20\)30367-6](https://doi.org/10.1016/S0140-6736(20)30367-6)
  20. Zucchella C, Sinforiani E, Tamburin S et al (2018) The multidisciplinary approach to Alzheimer's disease and dementia. a narrative review of non-pharmacological treatment. *Front Neurol*. <https://doi.org/10.3389/fneur.2018.01058>
  21. Power JD, Schlaggar BL (2017) Neural plasticity across the lifespan. *Wiley Interdiscip Rev Dev Biol*. <https://doi.org/10.1002/wdev.216>
  22. Pascual-Leone A, Freitas C, Oberman L et al (2011) Characterizing brain cortical plasticity and network dynamics across the age-span in health and disease with TMS-EEG and TMS-fMRI. *Brain Topogr* 24:302. <https://doi.org/10.1007/s10548-011-0196-8>
  23. Huang Y-Z, Lu M-K, Antal A et al (2017) Plasticity induced by non-invasive transcranial brain stimulation: a position paper. *Clin Neurophysiol* 128:2318–2329. <https://doi.org/10.1016/j.clinph.2017.09.007>
  24. Cabeza R, Albert M, Belleville S et al (2018) Maintenance, reserve and compensation: the cognitive neuroscience of healthy ageing. *Nat Rev Neurosci* 19:772–772. <https://doi.org/10.1038/s41583-018-0087-z>
  25. Menardi A, Pascual-Leone A, Fried PJ, Santarnecchi E (2018) The role of cognitive reserve in Alzheimer's disease and aging: a multi-modal imaging review. *J Alzheimers Dis* 66:1341–1362. <https://doi.org/10.3233/JAD-180549>
  26. Nelson ME, Jester DJ, Petkus AJ, Andel R (2021) Cognitive reserve, Alzheimer's neuropathology, and risk of dementia: a systematic review and meta-analysis. *Neuropsychol Rev*. <https://doi.org/10.1007/s11065-021-09478-4>
  27. Gutches A (2014) Plasticity of the aging brain: new directions in cognitive neuroscience. *Science* 346:579–582. <https://doi.org/10.1126/science.1254604>
  28. Barker AT, Jalinous R, Freeston IL (1985) Non-invasive magnetic stimulation of human motor cortex. *The Lancet* 325:1106–1107. [https://doi.org/10.1016/S0140-6736\(85\)92413-4](https://doi.org/10.1016/S0140-6736(85)92413-4)
  29. Gangitano M, Valero-Cabré A, Tormos J et al (2002) Modulation of input-output curves by low and high frequency repetitive transcranial magnetic stimulation of the motor cortex. *Clin Neurophysiol Off J Int Fed Clin Neurophysiol*. [https://doi.org/10.1016/s1388-2457\(02\)00109-8](https://doi.org/10.1016/s1388-2457(02)00109-8)
  30. Valero-Cabré A, Amengual JL, Stengel C et al (2017) Transcranial magnetic stimulation in basic and clinical neuroscience: a comprehensive review of fundamental principles and novel insights. *Neurosci Biobehav Rev* 83:381–404. <https://doi.org/10.1016/j.neubiorev.2017.10.006>
  31. Lefaucheur JP, Aleman A, Baeken C et al (2020) Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014–2018). *Clin Neurophysiol* 131:474–528. <https://doi.org/10.1016/j.clinph.2019.11.002>
  32. Lusicic A, Schruers KR, Pallanti S, Castle DJ (2018) Transcranial magnetic stimulation in the treatment of obsessive-compulsive disorder: current perspectives. *Neuropsychiatr Dis Treat* 14:1721. <https://doi.org/10.2147/NDT.S121140>
  33. Buss SS, Fried PJ, Pascual-Leone A (2019) Therapeutic non-invasive brain stimulation in Alzheimer's disease and related dementias. *Curr Opin Neurol* 32:292. <https://doi.org/10.1097/WCO.0000000000000669>
  34. Payesko J (2019) FDA Advisory Panel Rejects Neuronix's neuroAD for Alzheimer disease. *Neurology live*. <https://www.neurologylive.com/view/fda-advisory-panel-rejects-neuronix-neuroad-for-alzheimer-disease>
  35. Chou Y, That VT, Sundman M (2020) A systematic review and meta-analysis of rTMS effects on cognitive enhancement in mild cognitive impairment and Alzheimer's disease. *Neurobiol Aging* 86:1–10. <https://doi.org/10.1016/j.neurobiolaging.2019.08.020>
  36. Chu C-S, Li C-T, Brunoni AR et al (2021) Cognitive effects and acceptability of non-invasive brain stimulation on Alzheimer's disease and mild cognitive impairment: a component network meta-analysis. *J Neurol Neurosurg Psychiatry* 92:195–203. <https://doi.org/10.1136/jnnp-2020-323870>
  37. Dong X, Yan L, Huang L et al (2018) Repetitive transcranial magnetic stimulation for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials. *PLoS One* 13:e0205704. <https://doi.org/10.1371/journal.pone.0205704>
  38. Lin Y, Jiang W-J, Shan P-Y et al (2019) The role of repetitive transcranial magnetic stimulation (rTMS) in the treatment of cognitive impairment in patients with Alzheimer's disease: a systematic review and meta-analysis. *J Neurol Sci* 398:184–191. <https://doi.org/10.1016/j.jns.2019.01.038>
  39. Wang X, Mao Z, Ling Z, Yu X (2020) Repetitive transcranial magnetic stimulation for cognitive impairment in Alzheimer's disease: a meta-analysis of randomized controlled trials. *J Neurol*. <https://pubmed.ncbi.nlm.nih.gov/31760522/>. Accessed 10 Nov 2020
  40. McClintock SM, Reti IM, Carpenter LL et al (2018) Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. *J Clin Psychiatry*. <https://doi.org/10.4088/JCP.16cs10905>
  41. Hampel VA, Perry G, Lista S (2019) The Alzheimer precision medicine initiative. *J Alzheimers Dis* 68:1–24. <https://doi.org/10.3233/JAD-181121>
  42. Cash RFH, Weigand A, Zalesky A et al (2020) Using brain imaging to improve spatial targeting of transcranial magnetic stimulation for depression. *Biol Psychiatry*. <https://doi.org/10.1016/j.biopsych.2020.05.033>
  43. Moreno-Ortega M, Kangarlu A, Lee S et al (2020) Parcel-guided rTMS for depression. *Transl Psychiatry* 10:1–6. <https://doi.org/10.1038/s41398-020-00970-8>
  44. Siddiqi SH, Taylor SF, Cooke D et al (2020) Distinct symptom-specific treatment targets for circuit-based neuromodulation. *Am J Psychiatry*. <https://doi.org/10.1176/appi.ajp.2019.19090915>
  45. Menardi A, Rossi S, Koch G et al (2022) Toward noninvasive brain stimulation 2.0 in Alzheimer's disease. *Ageing Res Rev* 75:101555. <https://doi.org/10.1016/j.arr.2021.101555>
  46. Holczer A, Németh VL, Vékony T et al (2020) Non-invasive brain stimulation in Alzheimer's disease and mild cognitive impairment—a state-of-the-art review on methodological characteristics and stimulation parameters. *Front Hum Neurosci*. <https://doi.org/10.3389/fnhum.2020.00179>
  47. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med*. <https://doi.org/10.1371/journal.pmed.1000100>
  48. Pernecky R, Wagenpfeil S, Komossa K et al (2006) Mapping scores onto stages: mini-mental state examination and clinical dementia rating. *Am J Geriatr Psychiatry* 14:139–144
  49. Cheng CPW, Wong CSM, Lee KK et al (2018) Effects of repetitive transcranial magnetic stimulation on improvement of cognition in elderly patients with cognitive impairment: a systematic review and meta-analysis. *Int J Geriatr Psychiatry* 33:e1–e13. <https://doi.org/10.1002/gps.4726>
  50. Fried PJ, Jannati A, Davila-Pérez P, Pascual-Leone A (2017) Reproducibility of single-pulse, paired-pulse, and intermittent theta-burst TMS measures in healthy aging, Type-2 diabetes,

- and Alzheimer's disease. *Front Aging Neurosci.* <https://doi.org/10.3389/fnagi.2017.00263>
51. Ozdemir RA, Boucher P, Fried PJ et al (2021) Reproducibility of cortical response modulation induced by intermittent and continuous theta-burst stimulation of the human motor cortex. *Brain Stimulat* 14:949–964. <https://doi.org/10.1016/j.brs.2021.05.013>
  52. Sanches C, Stengel C, Godard J et al (2021) Past, present, and future of non-invasive brain stimulation approaches to treat cognitive impairment in neurodegenerative diseases: time for a comprehensive critical review. *Front Aging Neurosci.* <https://doi.org/10.3389/fnagi.2020.578339>
  53. Weiler M, Stieger KC, Long JM, Rapp PR (2020) Transcranial magnetic stimulation in Alzheimer's disease: are we ready? *eNeuro.* <https://doi.org/10.1523/ENEURO.0235-19.2019>
  54. Ahmed MA, Darwish ES, Khedr EM et al (2012) Effects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer's dementia. *J Neurol* 259:83–92. <https://doi.org/10.1007/s00415-011-6128-4>
  55. Bagattini C, Zanni M, Barocco F et al (2020) Enhancing cognitive training effects in Alzheimer's disease: rTMS as an add-on treatment. *Brain Stimulat* 13:1655–1664. <https://doi.org/10.1016/j.brs.2020.09.010>
  56. Brem A-K, Di Iorio R, Fried PJ et al (2020) Corticomotor plasticity predicts clinical efficacy of combined neuromodulation and cognitive training in Alzheimer's disease. *Front Aging Neurosci.* <https://doi.org/10.3389/fnagi.2020.00200>
  57. Cotelli M, Calabria M, Manenti R et al (2011) Improved language performance in Alzheimer disease following brain stimulation. *J Neurol Neurosurg Psychiatry* 82:794–797. <https://doi.org/10.1136/jnnp.2009.197848>
  58. Koch G, Bonni S, Pellicciari MC et al (2018) Transcranial magnetic stimulation of the precuneus enhances memory and neural activity in prodromal Alzheimer's disease. *Neuroimage* 169:302–311. <https://doi.org/10.1016/j.neuroimage.2017.12.048>
  59. Lee J, Choi BH, Oh E et al (2016) Treatment of Alzheimer's disease with repetitive transcranial magnetic stimulation combined with cognitive training: a prospective, randomized, double-blind, placebo-controlled study. *J Clin Neurol* 12:57–64. <https://doi.org/10.3988/jcn.2016.12.1.57>
  60. Rabey JM, Dobronevsky E, Aichenbaum S et al (2013) Repetitive transcranial magnetic stimulation combined with cognitive training is a safe and effective modality for the treatment of Alzheimer's disease: a randomized, double-blind study. *J Neural Transm* 120:813–819. <https://doi.org/10.1007/s00702-012-0902-z>
  61. Rutherford G, Lithgow B, Moussavi Z (2015) Short and long-term effects of rTMS treatment on Alzheimer's disease at different stages: a pilot study. *J Exp Neurosci.* <https://doi.org/10.4137/JEN.S24004>
  62. Sabbagh M, Sadowsky C, Touse B et al (2019) Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease. *Alzheimers Dement.* <https://doi.org/10.1016/j.jalz.2019.08.197>
  63. Wu Y, Xu W, Liu X et al (2015) Adjunctive treatment with high frequency repetitive transcranial magnetic stimulation for the behavioral and psychological symptoms of patients with Alzheimer's disease: a randomized, double-blind, sham-controlled study. *Shanghai Arch Psychiat* 27:9
  64. Xingxing L, Gangqiao Q, Chang Y et al (2021) Cortical plasticity is correlated with cognitive improvement in Alzheimer's disease patients after rTMS treatment. *Brain Stimulat* 14:503–510. <https://doi.org/10.1016/j.brs.2021.01.012>
  65. Zhang F, Qin Y, Xie L et al (2019) High-frequency repetitive transcranial magnetic stimulation combined with cognitive training improves cognitive function and cortical metabolic ratios in Alzheimer's disease. *J Neural Transm* 126:1081–1094. <https://doi.org/10.1007/s00702-019-02022-y>
  66. Zhao J, Li Z, Cong Y et al (2017) Repetitive transcranial magnetic stimulation improves cognitive function of Alzheimer's disease patients. *Oncotarget* 8:33864. <https://doi.org/10.18632/oncotarget.13060>
  67. Balsis S, Bengel JF, Lowe DA et al (2015) How do scores on the ADAS-Cog, MMSE, and CDR-SOB correspond? *Clin Neuropsychol* 29(7):1002–1009
  68. Suurmond R, van Rhee H, Hak T (2017) Introduction, comparison, and validation of Meta-Essentials: a free and simple tool for meta-analysis. *Res Synth Methods* 8:537–553. <https://doi.org/10.1002/jrsm.1260>
  69. Borenstein M, Hedges LV, Higgins JP, Rothstein HR (2021) Introduction to meta-analysis. John Wiley and Sons
  70. Duval S, Tweedie R (2000) A nonparametric, "Trim and Fill" method of accounting for publication bias in meta-analysis. *J Am Stat Assoc* 95:89–98. <https://doi.org/10.1080/01621459.2000.10473905>
  71. Higgins JPT, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ.* <https://doi.org/10.1136/bmj.d5928>
  72. Rossi Antal A, Bestmann S et al (2021) Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: expert guidelines. *Clinical Neurophysiol* 132(1):269–306
  73. Rossi S, Hallett M, Rossini PM et al (2009) Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. *Clin Neurophysiol* 120:2008. <https://doi.org/10.1016/j.clinph.2009.08.016>
  74. Hampel VA, Caraci F et al (2021) Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. *Neuropharmacology* 185:108081. <https://doi.org/10.1016/j.neuropharm.2020.108081>
  75. Hampel OS, Durrleman S et al (2017) A Precision Medicine Initiative for Alzheimer's disease: the road ahead to biomarker-guided integrative disease modeling. *Climacteric J Int Menopause Soc.* <https://doi.org/10.1080/13697137.2017.1287866>
  76. Lukiw WJ, Vergallo A, Lista S et al (2020) Biomarkers for Alzheimer's disease (AD) and the application of precision medicine. *J Pers Med.* <https://doi.org/10.3390/jpm10030138>
  77. Burke MJ, Fried PJ, Pascual-Leone A (2019) Transcranial magnetic stimulation: neurophysiological and clinical applications. *Handb Clin Neurol* 163:73–92. <https://doi.org/10.1016/B978-0-12-804281-6.00005-7>
  78. Pini L, Manenti R, Cotelli M et al (2018) Non-invasive brain stimulation in dementia: a complex network story. *Neurodegener Dis* 18:281–301. <https://doi.org/10.1159/000495945>
  79. Langs G, Wang D, Golland P et al (2016) Identifying shared brain networks in individuals by decoupling functional and anatomical variability. *Cereb Cortex N Y NY* 26:4004. <https://doi.org/10.1093/cercor/bhv189>
  80. Medaglia JD, Erickson B, Zimmerman J, Kelkar A (2020) Personalizing neuromodulation. *Int J Psychophysiol Off J Int Organ Psychophysiol* 154:101. <https://doi.org/10.1016/j.ijpsycho.2019.01.002>
  81. Tong T, Aganj I, Ge T et al (2017) Functional density and edge maps: characterizing functional architecture in individuals and improving cross-subject registration. *Neuroimage* 158:346. <https://doi.org/10.1016/j.neuroimage.2017.07.019>
  82. Gratton C, Laumann TO, Nielsen AN et al (2018) Functional brain networks are dominated by stable group and individual factors, not cognitive or daily variation. *Neuron* 98:439. <https://doi.org/10.1016/j.neuron.2018.03.035>

83. Finn ES, Shen X, Scheinost D et al (2015) Functional connectome fingerprinting: identifying individuals using patterns of brain connectivity. *Nat Neurosci* 18:1664–1671. <https://doi.org/10.1038/nn.4135>
84. Nestor SM, Blumberger DM (2020) Mapping symptom clusters to circuits: toward personalizing TMS targets to improve treatment outcomes in depression. *Am J Psychiatry*. <https://doi.org/10.1176/appi.ajp.2020.20030271>
85. Momi D, Ozdemir RA, Tadayon E et al (2021) Network-level macroscale structural connectivity predicts propagation of transcranial magnetic stimulation. *Neuroimage* 229:117698. <https://doi.org/10.1016/j.neuroimage.2020.117698>
86. Borenstein M (2009) Effect sizes for continuous data. The handbook of research synthesis and meta-analysis, 2nd edn. Russell Sage Foundation, New York, pp 221–235
87. Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. *BMJ* 327:557. <https://doi.org/10.1136/bmj.327.7414.557>
88. Borenstein M, Higgins JPT (2013) Meta-Analysis and Subgroups. *Prev Sci* 2:134–143. <https://doi.org/10.1007/s1121-013-0377-7>
89. Nikolakopoulou A, Mavridis D, Salanti G (2014) Demystifying fixed and random effects meta-analysis. *Evid Based Ment Health* 17:53–57. <https://doi.org/10.1136/eb-2014-101795>
90. Raudenbush SW (2009) Analyzing effect sizes: random-effects models. In: The handbook of research synthesis and meta-analysis, 2nd edn. Russell Sage Foundation, New York, pp 295–315
91. Thut G, Pascual-Leone A (2010) Review of combined TMS-EEG studies to characterize lasting effects of repetitive TMS and assess their usefulness in cognitive and clinical neuroscience. *Brain Topogr* 22(4):219–232
92. Fitzgerald PB, Hoy KE, Reynolds J et al (2020) A pragmatic randomized controlled trial exploring the relationship between pulse number and response to repetitive transcranial magnetic stimulation treatment in depression. *Brain Stimulat* 13:145–152. <https://doi.org/10.1016/j.brs.2019.09.001>
93. Corp D, Bereznicki H, Clark G et al (2021) Large-scale analysis of interindividual variability in single and paired-pulse TMS data. *Clin Neurophysiol Off J Int Fed Clin Neurophysiol*. <https://doi.org/10.1016/j.clinph.2021.06.014>
94. Cheeran B, Talelli P, Mori F et al (2008) A common polymorphism in the brain-derived neurotrophic factor gene (BDNF) modulates human cortical plasticity and the response to rTMS. *J Physiol* 586:5717–5725. <https://doi.org/10.1113/jphysiol.2008.159905>
95. Fitzpatrick AWP, Falcon B, He S et al (2017) Cryo-EM structures of tau filaments from Alzheimer's disease. *Nature* 547:185–190. <https://doi.org/10.1038/nature23002>
96. Kearney-Ramos TE, Lench DH, Hoffman M et al (2018) Gray and white matter integrity influence TMS signal propagation: a multimodal evaluation in cocaine-dependent individuals. *Sci Rep* 8:1–11. <https://doi.org/10.1038/s41598-018-21634-0>
97. Wilson MT, Fulcher BD, Fung PK et al (2018) Biophysical modeling of neural plasticity induced by transcranial magnetic stimulation. *Clin Neurophysiol* 129:1230–1241. <https://doi.org/10.1016/j.clinph.2018.03.018>
98. Aberra AS, Wang B, Grill WM, Peterchev AV (2018) Simulation of transcranial magnetic stimulation in head model with morphologically-realistic cortical neurons. *bioRxiv*. <https://doi.org/10.1101/506204>
99. Gomez-Tames J, Laakso I, Hirata A (2020) Review on biophysical modelling and simulation studies for transcranial magnetic stimulation. *Phys Med Biol* 65:24TR03. <https://doi.org/10.1088/1361-6560/aba40d>
100. Bijsterbosch JD, Barker AT, Lee K-H, Woodruff PWR (2012) Where does transcranial magnetic stimulation (TMS) stimulate? Modelling of induced field maps for some common cortical and cerebellar targets. *Med Biol Eng Comput* 50:671–681. <https://doi.org/10.1007/s11517-012-0922-8>
101. Janssen AM, Oostendorp TF, Stegeman DF (2014) The effect of local anatomy on the electric field induced by TMS: evaluation at 14 different target sites. *Med Biol Eng Comput* 52:873–883. <https://doi.org/10.1007/s11517-014-1190-6>
102. Bagarinao E, Watanabe H, Maesawa S et al (2020) Identifying the brain's connector hubs at the voxel level using functional connectivity overlap ratio. *Neuroimage* 222:117241. <https://doi.org/10.1016/j.neuroimage.2020.117241>
103. Lynch CJ, Breeden AL, Gordon EM et al (2019) Precision inhibitory stimulation of individual-specific cortical hubs disrupts information processing in humans. *Cereb Cortex* 29:3912–3921. <https://doi.org/10.1093/cercor/bhy270>
104. Sale MV, Mattingley JB, Zalesky A, Cocchi L (2015) Imaging human brain networks to improve the clinical efficacy of non-invasive brain stimulation. *Neurosci Biobehav Rev* 57:187–198. <https://doi.org/10.1016/j.neubiorev.2015.09.010>
105. Fox MD, Buckner RL, Liu H et al (2014) Resting-state networks link invasive and noninvasive brain stimulation across diverse psychiatric and neurological diseases. *Proc Natl Acad Sci USA* 111:E4367. <https://doi.org/10.1073/pnas.1405003111>
106. Pievani M, Pini L, Cappa SF, Frisoni GB (2016) Brain networks stimulation in dementia: insights from functional imaging. *Curr Opin Neurol* 29:756–762. <https://doi.org/10.1097/WCO.0000000000000387>
107. Ding Z, Ouyang G, Chen H, Li X (2020) Closed-loop transcranial magnetic stimulation of real-time EEG based on the AR mode method. *Biomed Phys Eng Express* 6:035010. <https://doi.org/10.1088/2057-1976/ab4a1c>
108. Shirinpour S, Alekseichuk I, Mantell K, Opitz A (2019) Experimental evaluation of methods for real-time EEG phase-specific transcranial magnetic stimulation. *bioRxiv*. <https://doi.org/10.1101/860874>
109. Veniero D, Vossen A, Gross J, Thut G (2015) Lasting EEG/MEG after effects of rhythmic transcranial brain stimulation: level of control over oscillatory network activity. *Front Cell Neurosci*. <https://doi.org/10.3389/fncel.2015.00477>
110. Zrenner B, Zrenner C, Caldana Gordon P et al (2020) Brain oscillation-synchronized stimulation of the left dorsolateral prefrontal cortex in depression using real-time EEG-triggered TMS. *Brain Stimulat* 13:197–205. <https://doi.org/10.1016/j.brs.2019.10.007>
111. Zrenner C, Desideri D, Belardinelli P, Ziemann U (2018) Real-time EEG-defined excitability states determine efficacy of TMS-induced plasticity in human motor cortex. *Brain Stimulat* 11:374–389. <https://doi.org/10.1016/j.brs.2017.11.016>